Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma
Michael Gérard, Aurélien Corroyer-Dulmont, Paul Lesueur, Solène Collet, Michel Chérel, Mickaël Bourgeois, Dinu Stefan, Elaine Johanna Limkin, Cécile Perrio, Jean-Sébastien Guillamo, et al.

To cite this version:
Michael Gérard, Aurélien Corroyer-Dulmont, Paul Lesueur, Solène Collet, Michel Chérel, et al.. Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma. Frontiers in Medicine, Frontiers media, 2019, 6:117, 10.3389/fmed.2019.00117. hal-02153761

HAL Id: hal-02153761
https://hal-normandie-univ.archives-ouvertes.fr/hal-02153761
Submitted on 10 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Severe hypoxia [oxygen partial pressure (pO$_2$) below 5–10 mmHg] is more frequent in glioblastoma multiforme (GBM) compared to lower-grade gliomas. Seminal studies in the 1950s demonstrated that hypoxia was associated with increased resistance to low–linear energy transfer (LET) ionizing radiation. In experimental conditions, the total radiation dose has to be multiplied by a factor of 3 to achieve the same cell lethality in anoxic situations. The presence of hypoxia in human tumors is assumed to contribute to treatment failures after radiotherapy (RT) in cancer patients. Therefore, a logical way to overcome hypoxia-induced radioresistance would be to deliver substantially higher doses of RT in hypoxic volumes delineated on pre-treatment imaging as biological target volumes (BTVs). Such an approach faces various fundamental, technical, and clinical challenges. The present review addresses several technical points related to the delineation of hypoxic zones, which include: spatial accuracy, quantitative vs. relative threshold, variations of hypoxia levels during RT, and availability of hypoxia tracers. The feasibility of hypoxia imaging as an assessment tool for early tumor response to RT and for predicting long-term outcomes is discussed. Hypoxia imaging for RT dose painting is likewise examined. As for the radiation oncologist’s point of view, hypoxia maps should be converted into dose-distribution objectives for RT planning. Taking into account the physics and the radiobiology of various irradiation beams, preliminary in silico studies are required to investigate the feasibility of dose escalation in terms of normal tissue tolerance before clinical trials are undertaken.

**Keywords:** glioblastoma, hypoxia, imaging, PET, MRI, radiation therapy
INTRODUCTION

Brain Tumors and Hypoxia

Brain tissue physiologically has a tissue pO\textsubscript{2} (ptO\textsubscript{2}) of ~40 mmHg, referred to as a normoxic or aerobic state. Hypoxia, generally defined when ptO\textsubscript{2} falls below 10 mmHg, is the result of an imbalance between oxygen consumption and delivery, a common situation in various types of malignancies.

Tumor growth was initially modeled by Gompertzian curves in the 1970s, in which the growth saturates when the tumor volume reaches the carrying capacity (1, 2). However, this model has some limitations and has been improved by incorporating various parameters such as angiogenesis and necrosis. A specific focus was placed on hypoxia, known to play a crucial role in tumor angiogenesis, genetic instability, and tumor invasion (3). More recently, hypoxia has also been shown to induce pro-tumoral activity by macrophage polarization (4). It is evident that hypoxia has a positive role in tumor growth and a negative role in therapeutic response (5) and is ultimately related to poor prognosis (6–8).

In primary brain tumors, hypoxia is also associated with malignant tumor growth. Glioblastoma multiforme (GBM), the most aggressive glioma and most frequent primary brain tumor, is particularly hypoxic. Using the Eppendorf needle electrode, previous works demonstrated that while the oxygenation in the normal brain ranges around 40 mmHg of oxygen, it falls below 10 mmHg in GBM (9, 10). However, hypoxic components are highly heterogeneous both within a single tumor and among patients. It has been proposed that tumors could be separated into three compartments: well oxygenated, acutely hypoxic, and chronically hypoxic (11).

Hypoxia also induces resistance to radiotherapy (RT) (12). In the early 1950s, Gray and colleagues reported that the radiosensitivity of mammalian cells was dependent on oxygen concentration (13). Hypoxia was therefore assumed to contribute to the failures after RT in cancer patients. It has also been suspected to be involved in resistance to various chemotherapies (14, 15). Explored solutions to target hypoxia included the use of hyperbaric oxygen chambers, hypoxic radiosensitizers, and, in recent years, hypoxia image-guided radiotherapy (HIGRT) (16).

More recently, various publications have demonstrated that hypoxia changes during tumor growth. Hypoxia is a result of an increased oxygen demand not only from tumor cells but also from immune cells, coupled with a perturbed vasculature (17). While in normal situations, the capillary density allows oxygen to be delivered to the cells with distances ranging from 30 to 60 \( \mu \)m, within a tumor, the distance to the closest capillary dramatically increases and causes a decrease in oxygen pressure. The concept of perfusion-limited hypoxia resulting from vessel obstruction and perturbed blood flow (poorly oxygenated blood) has introduced the concept of dynamic or cycling hypoxia (18–20). Temporal instability of ptO\textsubscript{2} has been observed with intermittent periods of reoxygenation. The kinetics of cycling hypoxia follow a complex timescale and occur with two frequencies: a few cycles per hour and cycles lasting from hours to days (21, 22). At present, no clear distinction exists between chronic and cycling hypoxia.

Hypoxia and Radiobiological Basis

In the presence of molecular oxygen at the time of or within microseconds after exposure, low-LET radiation ionizes water molecules, producing high-energy electrons and highly reactive oxygen species (ROS) (23). DNA damage results from either a direct or an indirect (via ROS) effect of irradiation. In the absence of oxygen, ROS are not produced, and DNA damage is reduced for a given RT dose. In vitro, the ratio of the doses yielding the same level of cell mortality in anoxic (100% N\textsubscript{2} atmosphere) vs.oxic (100% O\textsubscript{2} atmosphere) conditions is 2.5–3, corresponding to the oxygen enhancement ratio (OER) (24–26). This “oxygen effect” is not associated with oxygen-dependent differences in DNA repair processes (27). Therefore, oxygen is considered as the strongest existing radiosensitizing agent. Hypoxic tumors are thus considered radioresistant and are harder to control with conventional RT doses.

OER and OER modeling: As a function of pO\textsubscript{2} and LET, OER increases nonlinearly with decreasing pO\textsubscript{2} as described by the Alper and Howard-Flanders formula (28) and with decreasing LET (27–29) (Figure 1). Under exposure to low-LET radiation, OER is around 2 for a pO\textsubscript{2} value of around 10–15 mmHg, and a maximum is reached with pO\textsubscript{2} <5 mmHg (30, 31). For high LET (over a few hundred keV/\( \mu \)m), OER remains around 1, whatever the pO\textsubscript{2} (29, 32). Thus, high-LET radiation therapy is supposed to be more efficient than low-LET conventional RT (photons or protons) when treating hypoxic tumors (33, 34). This could be explained by the in situ “oxygen production in the heavy ion track” phenomenon (35–38).

For a precise modeling of OER dependence, a rigorous analysis should include several parameters: ptO\textsubscript{2} in both the
hypoxic and aerobic conditions, LET, cell survival end point, dose per fraction, particle species, tissue, and cell cycle phase. These variables are derived from in vitro survival data and may overestimate or underestimate the effects of hypoxia in vivo. Due to the complexity of dependencies, results of experimental data on OER measurements possess significant uncertainty. Improved understanding of the physical and chemical basis of the OER would add useful information on top of current empirical models. An accurate OER model is necessary to calculate doses necessary for RT dose escalation. Numerous mathematical OER models have been proposed, based on a range of experimental data from literature. However, the optimal mathematical function remains unknown, and estimation remains empirical. Once known, the model will be of invaluable aid to radiation oncologists in performing “hypoxia dose painting” in treatment planning for photon and ion beam RT.

Characterizing the heterogeneity of hypoxia necessitates tools with good temporal and spatial resolution to enable its eventual use in personalized medicine. Medical imaging is a promising tool, as it allows repeated noninvasive measurements to track both the temporal and spatial heterogeneity of tumor hypoxia. This is particularly relevant in RT, where constant technological advancements may permit treatment personalization based on the local ptO₂. There are, however, numerous points that require validation before using imaging of hypoxia for radiation therapy guidance.

### MAPPING OF HYPOXIA IN CLINICAL SITUATIONS: CURRENT DEVELOPMENTS

Various approaches have been designed to assess hypoxia in tissues. The use of implantable probes or needles is still the gold standard for ptO₂ measurement. In a clinical environment, however, tissue ptO₂ cannot be mapped with probes, and biomedical imaging based on positron-emission tomography (PET) and magnetic resonance imaging (MRI) serves as a surrogate biomarker of hypoxia or of cerebral oxygenation.

| Advantages                                                                 | Limitations                                                                 |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| **StO₂**                                                                  | • Easy setup and application in clinical routine                           |
| • Sensitive                                                               | • Indirect assessment of ptO₂                                              |
| • Assuming fully oxygenated arterial blood, the fraction of deoxygenated  | • Specificity for hypoxia needs to be validated                           |
| blood corresponds to the OEF                                              | • Spatial resolution is better than PET biomarkers                         |
| • Spatial resolution is better than PET biomarkers                         | • Injection of a radioactive compound                                     |
| **OER-MRI**                                                               | • Relatively prolonged time before steady-state acquisition (2h)          |
| • Showed promising results in the characterization of intratumor hypoxia  | • Spatial resolution                                                      |
| • Heterogeneity in one GBM model                                          | • Injection of a radioactive compound                                     |
| • Spatial resolution is better than PET biomarkers                         | • Needs to be validated in a more important number of studies             |
| • Spatial resolution is better than PET biomarkers                         | • Spatial resolution                                                      |
| **MOBILE**                                                                | • Injection of a radioactive compound                                     |
| • No need to inject contrast agent                                         | • Not recommended for brain tumors                                        |
| • Spatial resolution is better than PET biomarkers                         | • Spatial resolution                                                      |
| **MR fingerprint**                                                        | • Specificity for hypoxia needs to be validated                           |
| • Multi-parametric (vascularization, oxygenation…)                        | • Spatial resolution                                                      |
| characterization with rapid acquisition                                    | • Injection of a radioactive contrast agent                               |
| • Spatial resolution is better than PET biomarkers                         | • Needs to be validated in a more important number of studies             |
| **15O-oxygen**                                                            | • Spatial resolution                                                      |
| • Allows direct quantification of OEF                                       | • Injection of a radioactive compound                                     |
| **[18F]-FMISO**                                                           | • Spatial resolution                                                      |
| • Current gold standard for hypoxia imaging                               | • Injection of a radioactive compound                                     |
| • Indicator of cellular hypoxia                                            | • Spatial resolution                                                      |
| **[18F]-FAZA**                                                            | • Injection of a radioactive compound                                     |
| • Indicator of cellular hypoxia                                            | • Spatial resolution                                                      |
| • More rapid clearance than [18F]-FMISO                                   | • Injection of a radioactive compound                                     |
| **[18F]-Hx4**                                                             | • Spatial resolution                                                      |
| • Indicator of cellular hypoxia                                            | • Not recommended for brain tumors                                        |
| • More hydrophilic tracer allowing more rapid clearance than [18F]-FMISO | • Spatial resolution                                                      |
| **[18F]-DFA**                                                             | • Injection of a radioactive contrast agent                               |
| • Indicator of cellular hypoxia                                            | • Needs to be validated in a more important number of studies             |
| • More hydrophilic tracer allowing more rapid clearance than [18F]-FMISO  | • Spatial resolution                                                      |
| **[62Cu][64Cu]-ATSM**                                                     | • Injection of a radioactive compound                                     |
| • Characterization of moderate hypoxia                                     | • Spatial resolution                                                      |
| • Promising tracer for imaging hypoxia thanks to its high membrane        | • Specificity for hypoxia is questionable                                 |
| permeability and low redox potential                                       | • Spatial resolution                                                      |

Table 1: Imaging biomarkers to evaluate oxygenation in glioblastoma: advantages and limitations.
However, confounding factors such as cerebral blood volume (CBV), tissular T2, and contrast agent leakage need further investigation (41). Oxygen-enhanced MRI (OE-MRI) is likewise useful, based on the correlation between hypoxia and the variation in longitudinal relaxation rate (ΔR1) during oxygen challenge (42). In a preclinical model of GBM, Fan et al. have shown that OE-MRI is able to show intratumoral hypoxic heterogeneity and present an interesting correlation of OE-MRI with hypoxia by histological staining (24). However, OE-MRI still has to be validated in other GBM models and in the clinical setting. Mapping of oxygen by imaging lipids relaxation enhancement (MOBILE) (25) has also been proposed and also needs validation. OE-MRI and MOBILE present the advantage of repeated measurements of oxygenation without the need for exogenous contrast agents. Recently, an original approach termed MR fingerprint has also been proposed, which simultaneously obtains data on CBV, mean vessel radius, and blood oxygen saturation and creates high-resolution parametric maps of the microvascular network of the brain (26).

**PET Markers**

PET can also be used to map the OEF with radioactive molecular oxygen (18O2) as a tracer. It can also be used to estimate ptO2 by mapping of tracers trapped in areas with low ptO2. This approach is achieved with a variety of PET tracers based on an imidazole structure such as 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO) (43, 44) and [18F]-fluoroazomycin arabinoside ([18F]-FAZA), the uptake of which depends on a ptO2 threshold (45). After cell penetration by passive diffusion, these tracers are reduced in a two-step process, with the first step being reversed if oxygen is present and with the tracer becoming irreversibly trapped in the absence of oxygen.

It takes time to visualize hypoxic regions using [18F]-FMISO or [18F]-FAZA due to lipophilicity and slow clearance in normoxic tissues. More recently, 3-[18F]fluoro-2-(4-(2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol ([18F]-HX4 or 18F-flortanidazole) (46) and 1-(2,2-dihydroxyethyl)-3-[18F]fluoropropyl)-2-nitroimidazol ([18F]-DiFA) (47) have been developed as more hydrophilic tracers with the potential advantages of shorter acquisition times. However, formal validation in clinical situations is required. Other radiopharmaceuticals have been described. Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) seems to be a promising tracer for imaging hypoxia thanks to its high membrane permeability and low redox potential. However, the selectivity of Cu-ATSM to hypoxia has been challenged and discussed (48). See Figure 2 for the chemical structures of the various PET tracers designed for hypoxia imaging.

**ROBUSTNESS AND ACCURACY OF AVAILABLE TECHNIQUES TO ASSESS HYPOXIA IN THE BRAIN**

MRI and PET biomarkers have the advantage of being available and regularly utilized in the clinics; however, in assessing hypoxia, they have several limitations, which presently hinder routine clinical utilization for RT dose modulation (Table 1).

**Limitation of MRI Markers**

Mapping StO2 or the OEF yields a continuous signal with high temporal and spatial resolutions, but the relationship to ptO2 is indirect, and vascular changes indirectly reflect tissue changes. In particular, their relationship depends on the dissociation curve of hemoglobin, which itself depends on pH and temperature, among other factors. For example, a lower blood pH or a higher blood temperature would lead to a higher blood ptO2 for the same blood oxygen saturation.

In addition, OE-MRI and MOBILE have to be validated in various GBM models and in the clinical setting. MR fingerprint has been validated in patients but only for a single slice; thus, further developments are necessary.

**Limitation of PET Markers**

Accessibility: One of the main drawbacks of the extensive use of PET tracers of hypoxia in oncology is that tracer production is cost-intensive and only available at selected centers, in part due to limited manufacturers.

**Poor Spatial Resolution**

As discussed in the review of Grimes et al. (49) the molecular effect of oxygen is in the range of nm to μm, while PET resolution is about 3–4 mm. This raises various concerns about the interpretation of the PET results. It was shown that the PET signal would be similar between two voxels if 25% of a voxel
Molecular oxygen, with its very short half-life, would in theory address the dynamic nature of tissue oxygenation. However, its access is limited to a few centers worldwide, and $^{18}O$ has a poor intrinsic spatial resolution in comparison to $^{18}F$.

In summary, while being of major importance for tumor growth and resistance to treatment, the mapping and routine assessment of hypoxia remains a challenge. Among the various markers, $^{[18}F\text{-FMISO}}$ PET remains the most extensively studied and most accurate approach to map hypoxia in the clinical situation (52), but for brain tumors where PET imaging is not standard practice, MRI may provide surrogate biomarkers of oxygenation.

HYPOXIA FROM THE RADIATION ONCOLOGIST’S POINT OF VIEW

Hypoxia and the Dose Painting Concept

At present, the same radiation dose is delivered to all subregions of the tumor volume regardless of their individual biology and radiosensitivity. The RT concept of dose painting involves adapting the dose prescriptions for tumor subvolumes as a function of the tumor's heterogeneous biology. This could be done with functional imaging that maps different dose–response levels (53) over anatomic contours provided by morphological imagery, resulting in a “biological target volume” (BTV), where dose escalation could be applied. Hypoxia imaging could be used to provide the level of $pO_2$ and, subsequently, the spatial distribution of potentially radioresistant regions (54). These hypoxic target volumes (HTVs) are given a higher dose to achieve better tumor control (54), taking care not to compromise normal tissue tolerance (55, 56). To counteract radioresistance associated with hypoxic tumors, radiation oncologists need accurate calculations of the biologically optimal RT doses.

The technical feasibility of optimizing RT plans has been well documented, mostly in head and neck cancers (57, 58). A similar study has never been done in gliomas.

To define the HTV, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images (Figure 3).

Dose Painting by Contour

Also called multilevel or subvolume boosting, DPBC defines the HTV by segmenting a volume based on an uptake threshold on hypoxia functional images. This approach delivers a uniform boost dose to hypoxic subvolumes (59). Pixels with intensities higher than a defined value are considered as potentially hypoxic volumes. The cutoff is based on an empirical uptake threshold relative to a well-oxygenated reference, such as tumor-to-muscle and tumor-to-blood ratios (>95% of normal tissue voxels had a tissue/blood ratio of ≤1.2) or $SUV>1.4$ (60, 61).

DPBC is the most common approach in studies for several reasons. First, it is easier to integrate into conventional clinical workflows using commercial RT treatment planning systems (TPS). Second, it is easier to prescribe uniform dose boost regions. Lastly, it is more robust to spatial errors (62). In practice, dose escalation is achievable for the vast majority of

**FIGURE 3** | The two main approaches of dose painting: by contour (DPBC) or by number (DPBN). For DPBC, added to the standard clinical dose level (in pink), the radiation oncologist manually delineates a uniform HTV (in black) corresponding to a subjective PET-uptake level threshold (dashed line). Note that both methods use PET images, but DPBN requires a mathematical data pre-processing step (*) that computes PET image into a “dose modulation map.” When performed, dose painting allows RT dosimetric simulation for optimal dose escalation.

Impact of Altered Blood Flow in Tracer Uptake

PET tracers are delivered to the hypoxic tumor cells via the bloodstream. However, GBM vascularization is highly perturbed, which could impact the tracer biodistribution, notably in anoxic areas without any functional vascularization where delivery of the tracer might not be achieved (50). This could result in a very low tracer uptake in highly hypoxic areas. Vessel permeability may also have an impact in tissue biodistribution if more hydrophilic tracers have to be used. Dynamic PET has been proposed as an alternative to address the issues of both tumor perfusion and hypoxia, but the increased duration of the examination is a limitation for its routine use.

Poor Temporal Resolution

The 109-min half-life of $^{18}F$ is hardly ideal for examining temporal resolution. In general, the radioactive nature and short half-lives of PET tracers make it difficult to assess the evolution of hypoxia over hours or days. For instance, a study on head and neck cancers demonstrated that variability in spatial uptake can occur between repeated $^{[18}F\text{-FMISO}}$ PET scans (51). These results could be either a reflection of the poor reproducibility of FMISO PET due to confounding influences (perfusion, permeability) or a reflection of cycling hypoxia.
processing steps (require specific algorithms and software for numerical 
these methods are much more complex than DPBC and 
(produced 
enable algorithms to compute the heterogeneous doses to be 
achieved through a mathematical transformation of the spatial 
voxels integrated in a “dose modulation map.” This is 
on a relationship between the intensities of neighboring 
Dose Painting by Numbers

DPBN is a voxel-by-voxel level dose prescription based on a relationship between the intensities of neighboring 
voxels integrated in a “dose modulation map.” This is 
achieved through a mathematical transformation of the spatial 
distribution of hypoxia from noninvasive methods such as 
PET scans, named “ptO₂ map.” The ptO₂ and OER levels 
enable algorithms to compute the heterogeneous doses to be 
prescribed (65, 66).

Several attempts have been made to estimate ptO₂ 
and include OER in RT treatment planning. However, 
these methods are much more complex than DPBC and 
require specific algorithms and software for numerical 
processing steps (67). Some methods are proposed (68) 
but remain subject to discussion (69). Some authors 
consider a linear transformation of the image intensity 
into a prescribed dose (65, 67), whereas others assume a 
“dose redistribution” between hypoxic and normoxic pixels 
resulting in the same average dose as a conventional RT 
plan (58, 62, 70).

For head and neck tumors, Toma-Dasu et al. used a 
nonlinearity approach, which considers that the relationship 
between [¹⁸F]-FMISO uptake and ptO₂ follows a hyperbolic 
function (65). This equation was adapted for brain tumors 
and fine-tuned patient by patient using two healthy regions 
of interest for calibration of the model (68). This approach 
enables the computation of ptO₂ maps. However, once ptO₂ 
maps are calculated, dose modulation maps must also be 
computed. To do this, authors reported an equation that links 
dose modulation to ptO₂ by incorporating the OER effect 
(65). Another approach used was to compute an inverted dose 
 prescription map that can be directly imported into the RT TPS 
without any modifications (71). To the best of our knowledge, 
these dose modulation maps have never been proposed for 
brain tumors.

To conclude, the adaption in clinical practice of both DPBC 
and DPBN to address tumor hypoxia remains to be validated 
before becoming a clinical routine.

Intensity-Modulated Radiation Therapy

In GBM, the standard RT dose prescription is 60 Gray, in 1.8– 
2 Gray daily fractions, administered 5 days per week for 6 weeks. 
However, radioresistance is almost constant, inevitably leading to 
subsequent tumor relapse (72). RT dose escalation is one of the 
avenues of research being explored to improve local control (73). 
Because GBMs are infiltrative, diffuse, and often diagnosed late, 
these usually require irradiation of large volumes encompassing 
normal brain tissue. Thus, increased doses may potentially lead to 
unacceptable radiation-induced toxicities (edema, inflammation, 
necrosis, etc.) and severe sequelae.

Several methods have been identified to overcome the dose- 
limiting tolerance of the brain, especially in the era of constant 
technological medical advancements. The improved resolution 
of MRIs allows better visualization of the brain anatomy and, 
in consequence, a more accurate delineation of organs at risk 
(OARs). Furthermore, newer RT planning techniques such as 
intensity-modulated radiation therapy (IMRT) make dose 
painting feasible. Compared to 3-D conformational radiotherapy 
(3-D-CRT), IMRT allows highly conformal dose distributions of 
X-rays in target volumes with low levels of radiation to the 
surrounding normal tissues (74) (Figures 1–4). Using IMRT, very 
steep dose gradients in tumor subvolumes without unacceptable 
increased doses to OARs are achievable (53, 63, 64, 75).

Boron neutron capture therapy (BNCT) is another way to 
enhance the dose delivery in the tumor while preserving 
surrounding tissues. It can be done by boron administration 
into the tumor via the intravenous route or by perioperative 
intratumoral injection. BNCT relies on epithermal neutrons, 
which below 10 keV are not toxic to healthy tissues. Excellent 
spatial distribution is, however, critical due to their lack of spatial 
selectivity, with depth distribution profiles like photons but with a 
3-fold biological efficacy, which can thus turn into a drawback if
not targeted properly. Also, obtaining only a low energy spectrum of neutrons (below 10 keV to protect healthy tissues) can be quite challenging, and specific equipment has been designed that might only be adequate for superficial tumors (10 cm deep). Recent approaches suggest that proton and carbon ion beams could also be used to produce epithermal neutrons at the site of boron capture within the tumor (76–80). Thus, the need for specific neutron therapy machines, which are likely inadequate for the treatment of deep-seated tumors, might be surpassed by the use of proton and carbon ion accelerators. BCNT techniques are being investigated by a few teams worldwide, mostly in Japan and Sweden.

While being relevant from a radiobiological point of view, the concept of HIGRT has not entered clinical routine utilization, with some limiting factors being the difficulties tied to OER modeling, $pO_2$ mapping, and evolution of hypoxia during the course of RT.

**REOXYGENATION STRATEGIES TO IMPROVE RT EFFICACY**

**Reoxygenation During the Course of RT**

The adaptation of RT based on hypoxia imaging also raises some questions about the evolution of hypoxia during the course of RT. Tumor reoxygenation is a phenomenon wherein cells that are hypoxic before RT become oxygenated during or after RT (81). For example, in head and neck cancers, it was recently published that during the course of RT, tumor hypoxia decreases (82). In this review, authors also discuss oxygenation in various tumor types, namely, lung, cervical, and rectal carcinomas. For these tumors, a decrease in hypoxia was likewise seen during RT. Thus, existing OER models do not incorporate variations of a tumor’s radiosensitivity or reoxygenation during the course of treatment.

Rapid reoxygenation affects acutely hypoxic cells, while slow reoxygenation affects chronically hypoxic cells. These two processes may provide specific windows of opportunity. The RT fraction should be delivered when tumor reoxygenation is expected to be at its maximum so as to optimize the OER. Consequently, the HTV may not be spatially fixed over time, and a single pre-treatment PET may not be pertinent, especially for adaptive RT (83). PET scans may be repeated (over 5–7 days) to monitor hypoxia dynamics during RT (84). To this aim, numerous studies, mostly in head and neck cancers, have been published (82). Consistent with the reoxygenation model, results show that PET hypoxia uptake decreases during RT (82). Increasing PET uptake during RT has been correlated with loco-regional failure (85–87); however, disappearance of hypoxia was not correlated with better prognosis (88, 89).

With regard to the reproducibility of intratumor uptake among repeated scans during RT, results are ambiguous, with a study reporting highly reproducible uptake (90) and another reporting high uptake variability (51). Nevertheless, repeat imaging during the course of treatment might improve measurements (83). It is clear that further work is required to understand the spatio-temporal intratumor distribution of radiotracers before and during RT.

**External Reoxygenation Strategies**

New radiosensitizing drugs and radio-enhancing nanoparticles may be delivered into the tumor to improve oxygenation. Among the radiosensitizers, some have been designed so as to overcome the effect of hypoxia by inducing reoxygenation of the tumor [reviewed in Graham and Unger (91)]. Of these, fluorochemicals can dissolve considerable amounts of oxygen and could be considered to deliver oxygen through passive diffusion in hypoxic regions. As an example, NVX-108 is a radiosensitizer composed of dodecafluoropentane (DDFP) exhibiting 200 times the oxygen carrying capacity compared to human hemoglobin (92), that demonstrated its promise in preclinical studies, with a clinical study ongoing for GBM.

Breathing of oxygen under normobaric or hyperbaric conditions has also been investigated. As discussed by Graham et al. hyperbaric oxygenation has an overall positive effect on RT but has not been adapted and remains to be validated as standard treatment. To further improve the reoxygenation, the use of carbogen has been proposed for GBM. However, overall results were unsatisfactory, and we recently demonstrated using advanced MRI that this failure was attributable to facilitated reoxygenation in the normal brain relative to the tumor (93).

In endogenous reoxygenation or external reoxygenation strategies, one can observe that hypoxia remains highly dynamic during the course of treatment. This reinforces the need for accurate imaging strategies that quantify temporal variations in tumor hypoxia to be able to adapt the RT regimen based on the hypoxic component of the tumor.

**INNOVATIVE RADIATION THERAPY MODALITIES TO OVERCOME HYPOXIA-INDUCED RADIORESISTANCE IN GBM**

The efficacy of photon-based RT critically depends on the presence of molecular oxygen. To achieve higher equivalent doses into the tumor, hadrontherapy such as proton therapy has also been proposed, advantageous due to its better spatial distribution and normal tissue sparing (and thus potential for accurate dose escalation). Carbon ion therapy is also a promising option, representing an increase in the biological efficacy of RT by a factor of 3 to 4 relative to photons, thus potentially overcoming radioresistance and achieving better tumor control while sparing healthy tissues.

**Proton Therapy**

The depth dose distribution of a proton beam, represented by the Bragg peak, can be used to reduce radiation exposure of healthy tissues beyond the tumor (94) (Figure 4). These properties are particularly relevant to pediatric malignancies and benign/low-grade intracranial tumors. However, GBMs are rapidly progressive, poorly limited tumors. Thus, proton therapy should be used carefully to avoid marginal misses, with careful monitoring of tumor volumes over the weeks of RT. The process of rescanning, and replanning if necessary, is called adaptive RT. Provided that such caution is employed, proton therapy may be used to perform dose escalation. Proton therapy has a relative
biological effectiveness (RBE) relative to high-energy photons of 1.1. Thus, protons are 10% more biologically efficient than high-energy photons. Although the OER of protons is similar to that of photons, the increased RBE might partially counteract the radioresistance of hypoxic areas. A dosimetric study indicated that for a subpopulation of patients with GBM, at least 90 Gray RBE (Gy RBE) could be delivered to the tumor with proton therapy, with only small volumes of normal brain structures receiving more than 70 Gy RBE. In a phase I–II proton therapy–based dose escalation study by Mizumoto et al. patients received photon-based RT or 250 MeV proton therapy (50.4 Gy RBE in 28 fractions) to a large tumor volume with a concomitant proton therapy boost (23.1 Gy RBE in 14 fractions) to MRI gadolinium-enhanced areas, which included hypoxic zones (95, 96). Overall, patients received a total dose of 96.6 Gy RBE in 56 fractions. The 1- and 2-year overall survival rates were 78% (95% CI, 61%–95%) and 43% (95% CI, 23%–63%), respectively, with a median survival of 21.0 months (range, 5.5–81.0 months; 95% CI, 16.1–25.9 months). This proof-of-concept study shows an overall survival gain of 6 months in comparison with historical series, but results have yet to be reproduced.

Carbon Ion Beam Irradiation
Carbon ions have, to an even higher degree, the spatial selectivity of protons and can exhibit a very high LET of ~100 keV/µ.m. Carbon ions are densely ionizing, releasing their energy in a constant and very close manner, contrary to photons or protons. They possess, physical doses being equal, a higher RBE (around 3), as they more likely interact with DNA and produce complex damage that is difficult or impossible to repair (97). This direct effect of carbon ions is less influenced by the presence of oxygen. OER values of hypoxic cells are, respectively, 1.5 for high-LET ions and 3.0 for X-rays. For a similar effect in hypoxic conditions, the dose needed for conventional RT is three times higher than in normoxic conditions, but such increase in dose is not achievable without compromising OAR dose limits. For carbon ions, the 1.5x increase needed is achievable. Preclinical studies have reported that accelerated heavy ion particles may have an advantage over X-rays in overcoming GBM radioresistance (98, 99). A phase I–II study combined 50 Gy X-ray RT with chemotherapy, followed by a carbon ion boost in the contrast enhancing region with doses from 16.8 to 24.8 Gray (RBE) (100). For the 32 GBM patients included, the median survival time was 17 months and reached 26 months for the high-dose group, with dose escalation having a significant impact. In line with these results, the randomized CLEOPATRA trial compares low- and high-LET irradiation in GBM patients (101).

Spatial Fractionation, Hypofractionation, and Flash Dose
Alternative approaches also include modulation of radiation delivery to deliver tumoricidal doses to large volumes, using adaptations that allow an enhanced differential effect between normal tissues and the tumor. Spatial fractionation has been identified as a promising approach to such aim. This is particularly relevant to GBMs because of the large volumes irradiated and the radiosensitivity of the brain (102–104). Specific devices are being designed and adapted on various types of treatment machines using different radiation modalities, including synchrotron radiation, very-high-energy electrons, and proton beams (either double scattering with a grid or with modified pencil beam scanning).

Hypofractionation has been originally defined as the use of doses above 2.5 Gy per fraction. However, the concept of hypofractionation has now been extended to very high doses per fraction using photon-based stereotactic irradiation. Fraction doses commonly use 3 times 20 Gy (in lung cancers) but may even use 90 Gy in a single fraction for conditions such as trigeminal neuralgia. An extension of the concept is a flash (ultra-high) dose that combines hypofractionation with a very high dose rate (105, 106). Animal models have consistently shown excellent skin sparing and tumor response equivalent to standard regimens (107, 108).

CONCLUSIONS
It is widely accepted that hypoxia is a poor prognostic factor in GBM. Among the key effects of hypoxia, radioresistance is a promising and potentially actionable factor. Imaging offers the opportunity to map tumor hypoxia or oxygenation before and during the course of RT and consequently opens an avenue for treatment adaptation. These adaptations can be by modulating doses based on 

\[ \text{O}_{2} \] and OER measurements, by introducing reoxygenation strategies in combination with conventional RT, or by adapting the RT techniques. All these developments require accurate characterization of hypoxia. In this review, we argue that while various strategies are being developed, at present, PET remains the most relevant strategy with the most evidence.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING
This work has been supported by the French national agency for research Investissements d’Avenir via grant Labex IRON n•ANR-11-LABX-0018-01 and Institut National du Cancer (INCa).

ACKNOWLEDGMENTS
The authors wish to thank Elmostafa Fadaili, Nicolas Pirault, and Yann Lauzin for their technical help.

REFERENCES
1. Simpson-Herren I, Lloyd HH. Kinetic parameters and growth curves for experimental tumor systems. *Cancer Chemother. Rep.* (1970) 54:143–74.
2. Norton L, Simon R, Breton RD, Bogden AE. Predicting the course of Gompertzian growth. *Nature.* (1976) 264:542–5. doi: 10.1038/264542a0
3. Pouységur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour
regression. *Nature.* (2006) 441:437–43. doi: 10.1038/nature04871

4. Leblond MM, Gérault AN, Corroyer-Dulmont A, MacKenzie ET, Petit E, Bernaudin M, et al. Hypoxia induces macrophage polarization and re-eduction toward an M2 phenotype in U87 and U251 glioblastoma models. *Oncoimmunology.* (2016) 5:e1058442. doi: 10.1080/2162402X.2015.1056442

5. Corroyer-Dulmont A, Chakhyoon A, Collet S, Durand L, MacKenzie ET, Petit E, et al. Imaging modalities to assess oxygen status in glioblastoma. *Front. Med.* (2015) 2:57. doi: 10.3938/fmed.2015.00057

6. Evans SM, Jenkins KW, Chen HJ, Jenkins WT, Judy KD, Hwang W-T, et al. The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: a pilot study. *Transl Oncol.* (2010) 3:160–9. doi: 10.1539/tlo.09.0265

7. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. *Clin. Cancer Res.* (2008) 14:2623–30. doi: 10.1158/1078-0432.CCR-07-0495

8. Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, et al. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using 18F-FMISO PET and MRI. *Clin Cancer Res.* (2016). doi: 10.1158/1078-0432.CCR-15-2529

9. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. *Int J Radiat Oncol Biol Phys.* (1994) 29:427–31. doi: 10.1016/0360-3016(94)90934-2

10. Collingridge DR, Piepmeier JM. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoral brain tissue. *Radiother Oncol.* (1999) 53:127–31. doi: 10.1016/S0167-8140(99)00121-8

11. Pobpe RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. *Int J Radiat Oncol Biol Phys.* (2002) 54:921–7. doi: 10.1016/S0360-3016(02)00079-9

12. Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. *J Radiat Res.* (2016) 57(Suppl. 1):i90–8. doi: 10.2307/3579024

13. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. *Br J Radiol.* (1953) 26:638–48. doi: 10.1259/bjr/6923007

14. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights of the outcome of radiotherapy. *Radiat Res.* (2000) 154:485–96. doi: 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2

15. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

16. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

17. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

18. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

19. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

20. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

21. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

22. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

23. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

24. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

25. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

26. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

27. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

28. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

29. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

30. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

31. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

32. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

33. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

34. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

35. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

36. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

37. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

38. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

39. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

40. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738

41. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* (2002) 2:120–30. doi: 10.1038/nrc738
44. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med. (2007) 37:451–61. doi: 10.1053/j.semnuclmed.2007.07.001

45. Tran L-B-A, Bol A, Labar D, Jordan B, Magat J, Mignon L, et al. Hypoxia imaging with the nitroimidazole 18F-FDFA PET tracer: a comparison with OxyLite EPR oximetry and 18F-MRI relaxometry. Radiother Oncol. (2012) 105:29–35. doi: 10.1016/j.radonc.2012.04.011

46. Wack LJ, Mönich D, van Elmp M, Zegers CML, Troost EGC, Zips D, et al. Comparison of [18F]FMISO, [18F]FAZA and [18F]HX4 for PET imaging of hypoxia—a simulation study. Acta Oncol. (2015) 54:1370–7. doi: 10.3109/0284186X.2015.1067721

47. Shimizu Y, Zhao S, Nishijima K-I, Matsumoto H, Shiga T, et al. A novel PET probe “[18F]DFA” accumulates in hypoxic region via glutathione conjugation following reductive metabolism. Mol Imaging Biol. (2018) 21:12–9. doi: 10.1007/s12149-018-1214-y

48. Colombié M, Gouard S, Frindel M, Vidal A, Chérel M, Kraeber-Bodéré F, et al. Focus on the controversial aspects of (64)Cu-ATSM in tumoral hypoxia mapping by PET imaging. Front Med. (2015) 2:58. doi: 10.3389/fmed.2015.00058

49. Grimes DR, Warren DR, Warren S. Hypoxia imaging and radiotherapy: bridging the resolution gap. Br J Radiol. (2017) 90:20160939. doi: 10.1259/bjr.20160939

50. Marcu LG, Moghadasi L, Bezak E. Imaging of tumor characteristics and molecular pathways with PET: developments over the last decade toward personalized cancer therapy. Int J Radiat Oncol Biol Phys. (2018) 102:1165–82. doi: 10.1016/j.ijrobp.2018.04.055

51. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. (2008) 70:235–42. doi: 10.1016/j.ijrobp.2007.08.036

52. Inubushi M, Tatsumi M, Yamamoto Y, Kato K, Tsujikawa T, Nishi R. European research trends in nuclear medicine. Ann Nucl Med. (2018) 32:579–82. doi: 10.1007/s12149-018-1303-7

53. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Fluorine-18 labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol. (2010) 97:176–82. doi: 10.1016/j.radonc.2010.04.012

54. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. (2008) 70:2–13. doi: 10.1016/j.ijrobp.2007.06.039

55. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol. (2012) 51:222–30. doi: 10.3109/0284186X.2011.599815

56. Powathil G, Kohandel M, Milesevic M, Sivalogathan S. Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies. Comput Math Methods Med. (2012) 2012:410602. doi: 10.1155/2012/410602

57. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol. (2003) 48:N31–35. doi: 10.1088/0031-9155/48/2/104

58. Chakl oyan A, Guillamo J-S, Collet S, Kauffmann F, Delcroix N, Lechapt-Zalcman E, et al. FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas. Sci Rep. (2017) 7:10210. doi: 10.1038/s41598-017-08646-y

59. Lindblom E, Dasu A, Uhrdin J, Even A, van Elmp M, Lambin P, et al. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy—the influence of the choice of the reference region and conversion function. Acta Oncol. (2015) 56:819–25. doi: 10.1080/0284186X.2017.1293289

60. Søvik A, Malinen E, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol. (2007) 52:499–513. doi: 10.1088/0031-9155/52/2/013

61. Arnesen MR, Knudtsen IS, Rekstad BL, Eilertsen K, Dale E, Bruheim K, et al. Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps. Acta Oncol. (2015) 54:1607–13. doi: 10.3109/0284186X.2015.1061690

62. Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: state of the art and future therapeutics. Surg Neurol Int. (2014) 5:843. doi: 10.4103/2152-7806.132138

63. Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys. (2014) 90:877–85. doi: 10.1016/j.ijrobp.2014.07.014

64. Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. (2009) 69:383–92. doi: 10.1158/0008-5472.CAN-07-6871

65. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Minton MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM–guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. (2001) 49:1171–82. doi: 10.1016/S0360-3016(00)01433-4

66. Sato T, Masunaga S-I, Komura H, Hamada N. Depth distributions of RBE-weighted dose and photon-isoeffective dose for boron neutron capture therapy, Radiat Prot Dosim. (2018) 183:247–50. doi: 10.1093/rd/ncy235

67. Safari-Naeini M, Chacon A, Guatelli S, Franklin DR, Bambery K, Gregoire V, et al. First experimental proof of proton boron capture therapy. Sci Rep. (2018) 8:16257. doi: 10.1038/s41598-018-34643-w

68. Zaidi L, Belgard M, Taskaev S, Khelifi R. Beam shaping assembly design of 7Li(p,n)7Be neutron source for boron neutron capture therapy of deep-seated tumors. Appl Radiat Isot. (2018) 139:316–24. doi: 10.1016/j.apradiso.2018.05.029

69. Cirrone GP, Manti L, Margarone D, Petringa G, Giuffrida L, Minopoli A, et al. First experimental proof of proton boron capture therapy
Hypoxia Imaging and Radiotherapy in Glioblastoma

Gérard et al.

supratentorial glioblastoma multiforme. *Int J Radiat Oncol Biol Phys.* (2010) 77:98–105. doi:10.1016/j.ijrobp.2009.04.054

Mizumoto M, Yamamoto T, Takano S, Ishikawa E, Matsumura A, Ishikawa H, et al. Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. *Pract Radiat Oncol.* (2015) 5:59–66. doi:10.1016/j.prro.2014.03.012

Orecchia R, Krengli M, Jereczek-Fossa BA, Frangetti S, Gerard JP. Clinical and research validity of hadrontherapy with ion beams. *Crit Rev Oncol Hematol.* (2004) 51:81–90. doi:10.1016/j.critrevonc.2004.04.005

Takahashi M, Hirakawa H, Yajima H, Izumi-Nakajima N, Okayasu R, Fujimori A. Carbon ion beam is more effective to induce cell death in sphere-type A127 human glioma cells compared with X-rays. *Int J Radiat Biol.* (2014) 91:1125–32. doi:10.3109/09553002.2014.927933

Combs SE, Zipp L, Rieken S, Habermann D, Bruns S, Winter M, et al. In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells. *Radiat Oncol.* (2012) 7:9. doi:10.1186/1748-717X-7-9

Mizoe J-E, Tsuji H, Hasegawa A, Yanagi T, Takagi R, Kamada T, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. *Int J Radiat Oncol Biol Phys.* (2007) 69:390–6. doi:10.1016/j.ijrobp.2007.03.003

Combs SE, Kieser M, Rieken S, Habermann D, Jakel O, Haberer T, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. *BMCM Cancer.* (2010) 10:478. doi:10.1186/1471-2407-10-478

Prezado Y, Jouvin G, Hardy D, Patriarca A, Nauraye C, Bergs J, et al. Proton minibeam radiation therapy spares normal rat brain: long-term clinical, radiological and histopathological analysis. *Sci Rep.* (2017) 7:14403. doi:10.1038/s41598-017-14786-y

Prezado Y, Fois G, Le Duc G, Bravin A. Gadolinium dose enhancement studies in microbeam radiation therapy. *Med Phys.* (2009) 36:3568–74. doi:10.1118/1.3166186

Bräuer-Krisch E, Serduc R, Sieghahn B, De Lucc G, Prezado Y, Bravin A, et al. Effects of pulsed, spatially fractionated, microscopic synchrotron X-ray beams on normal and tumoral brain tissue. *Mutat Res.* (2010) 704:160–6. doi:10.1111/j.1602-0645.2009.02138.x

Patriarca A, Fouillade C, Auger M, Martin F, Pouzoulet F, Nauraye C, et al. Experimental set-up for FLASH proton irradiation of small animals using a clinical system. *Int J Radiat Oncol Biol Phys.* (2018) 102:619–26. doi:10.1016/j.ijrobp.2018.06.043

Durante M, Bräuer-Krisch E, Hill M. Faster and safer? FLASH ultra-high dose rate in radiotherapy. *Br J Radiol.* (2018) 91:20170628. doi:10.1259/bjr.20170628

Vozenin M-C, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond J-F, et al. The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients. *Clin Cancer Res.* (2019) 25:35–42. doi:10.1158/1078-0432.CCR-17-3735

Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond J-F, Petit B, et al. Irradiation in a flash: unique sparing of memory in mice after whole-body irradiation in mini-pig and cat-cancer patients. *Radiother Oncol.* (2018) 124:365–9. doi:10.1016/j.radonc.2017.05.003

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.